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The proposal that the transmissible agent in prion
diseases can be a conformationally altered host pro-
tein that multiplies by autocatalytic conversion has
gained wide acceptance. Recent work shows that the
agent, the prion, can be replicated in a cell-free sys-
tem, that it can be generated de novo, and that the
strain-specific properties of prions are encoded by
conformational variations of the underlying protein.
In the second half of the 19th century, the concept of
spontaneous generation, namely that life could arise
from inanimate substance, was laid to rest by the inci-
sive experiments of Louis Pasteur. While one would
hesitate to categorize viruses and prions as living, they
do have the ability to propagate indefinitely, albeit with
a little help from their hosts, and to perpetuate their
properties while adapting to changing environment, in-
disputably characteristic attributes of living entities.
Whereas viruses follow the precept “omne vivum ex
vivo,” recent findings, to be discussed in this review,
reinforce the proposition that prions do not.
Prions are the causative agents of transmissible
spongiform encephalopathies (TSEs) such as Creutz-
feldt-Jakob disease (CJD) in man, bovine spongiform
encephalopathy (BSE) in cattle, or scrapie in sheep.
Their unusual resistance to radiation led early on to the
proposal that they might be devoid of nucleic acid and
consist only of protein. The discovery of PrPSc, a pro-
tein found only in TSE-infected organisms, the cloning
of PrP cDNA and the cognate gene, the recognition that
this gene encodes a normal host protein, PrPC, from
which PrPSc is derived by conformational rearrange-
ment, and the linkage between PrP gene and familial
prion disease supported the suggestion that PrPSc or
some abnormal conformer of PrPC (generically desig-
nated as PrP*) is the main or perhaps only constituent
of the prion. Transgenic experimentation strengthened
the link between the PrP gene and prion disease by
showing that the so-called species barrier could be
overcome by introducing the PrP gene of the donor into
the recipient, and the essential role of PrP in prion dis-
ease was established by the finding that PrP knockout
mice were resistant to disease and incapable of propa-
gating prions (reviewed in Weissmann, 2004).
The “protein-only” hypothesis proposes that the in-
fectious, abnormal conformer of PrPC is propagated
autocatalytically and a specific mechanism is sug-
gested by the “seeding hypothesis” (Figure 1).
Biology of Mammalian Prions
We distinguish four processes in prion infection, namely
penetration, translocation, multiplication, and pathogen-*Correspondence: charlesw@scripps.eduesis. Experimentally, prions are mostly transmitted by
intracerebral or intraperitoneal injection, while under “nat-
ural” circumstances mammalian prions are usually
taken up orally. After penetrating the lining of the gas-
trointestinal tract they enter the lymphoreticular tissue
of the gut, invade the peripheral nervous system, either
directly or via lymph nodes and spleen, and ascend the
central nervous system (CNS) (Aguzzi, 2003). Prions
multiply to high titers in the brain and in some hosts in
spleen, albeit to a lower level. Spongiform degenera-
tion, astrocytosis, and neuronal cell death accompany
prion multiplication in the CNS; the pathogenic mecha-
nism is still unclear, but it is not due to depletion of
PrPC. Prion multiplication and translocation require ex-
pression of PrPC in the tissues involved, and while pri-
ons have been detected in the blood, the role of the
circulation in spreading infection is unclear. Although
penetration, translocation, and multiplication in the pe-
riphery occur rapidly (within days to weeks in the mouse),
clinical symptoms are only apparent after months in the
mouse and years to decades in man.
The prion gene occurs in various polymorphic forms
and several such polymorphisms affect susceptibility
to disease and incubation time. Moreover, in humans
there are a number of rare PrP mutations that are linked
to familial forms of prion disease (Gambetti et al., 2003).
Trans-species prion transmission is frequently re-
stricted by a “transmission barrier” that is evidenced
by extended incubation time, incomplete attack rate, or
absence of clinical disease. However, despite absence
of clinical symptoms, prion replication, PrPSc accumu-
lation, and histopathological changes may occur late
after infection (Hill and Collinge, 2003).
A remarkable phenomenon is the existence of dis-
tinct prion strains, originally characterized by the incu-
bation time and the neuropathology they elicit in a par-
ticular host (Bruce, 2003).
Biology of Yeast Prions
The realization that certain proteins in fungi could
switch to an alternative, largely nonfunctional confor-
mation and that this conformational change was herita-
ble led to the concept of the “yeast prion” because of
the resemblance to the mechanism postulated for
mammalian prion multiplication (Wickner et al., 2004).
Indeed, the “prion conformation” of proteins such as
ure2p or sup35p is characterized by partial protease
resistance and aggregation to amyloid filaments. How-
ever, there is no similarity between the amino acid se-
quences of mammalian PrP and of yeast prions. More-
over, mammalian prions are infectious agents that can
invade organisms from without, whereas yeast prions
do not naturally infect cells, although they can be intro-
duced artificially. The yeast “prion phenomenon” has
nonetheless provided deep insight into the process of
conversion of proteins to fibrillar amyloids and estab-
lished the validity of the seeding hypothesis.
Multiplication of Mammalian Prions
The protein-only hypothesis proposes that the main or
perhaps only constituent of the mammalian prion is a
conformational variant of PrPC, commonly designated
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as PrPSc or PrP-res (the noncommittal designation PrP* r
is preferable). i
The three-dimensional structure of recombinant PrPC (
is characterized by three α helices, a short β-pleated a
region, and a long unstructured portion comprising al- t
most half of the molecule. Natural PrPC is fully or par- p
tially N glycosylated in two positions and anchored to h
the outer surface of the cell membrane by a glycosyl- r
phosphatidyl inositol anchor; however, transmembrane e
configurations ((ctm)PrP) also occur. t
PrPSc is defined as an aggregated form of PrP that is m
largely resistant to proteinase K (PK) digestion under t
conditions where PrPC and most other proteins are t
readily degraded. PrPSc contains about 50% β sheet w
structure; because of its insolubility, its three-dimen- t
sional structure could not yet be elucidated. Digestion e
of PrPSc by PK causes cleavage between residues 87 t
and 91 (depending on the prion strain), leading to a p
characteristic electrophoretic mobility shift of the three o
bands corresponding to di-, mono-, and unglycosy- o
tlated species (designated PrP27–30).w
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Figure 1. Seeding Model for Prion Strain Perpetuation, Strain Shift,
tand Strain Incompatibility
t
PrPC is in equilibrium with PrPAC (PrP in “amyloidogenic conforma-
ation”) (Uversky and Fink, 2004), the equilibrium strongly favoring
pPrPC. The seeds in all cases are PrPSc fibrils of “strain 1” (green).
i(A) Strain perpetuation. The host cell contains PrPC of type a (pur-
ple) that may, but need not, have the same sequence as the infect- a
ing PrPSc. PrPC can adopt a conformation with a “donor site” (con- c
vex protuberance) that fits into the “acceptor surface” (concave m
niche) of the PrPSc fibril. In doing so, the PrPC forms an identical
macceptor surface to which a further monomer can add. The newly
sformed fibrils are of strain 1.
b(B) Strain switch. The host cell contains PrPC of type b (red) that
has a different sequence than the PrPSc introduced into the organ- i
ism. The PrPC can more or less readily adopt a conformation with i
a donor site that fits into the acceptor surface of the PrPSc; how- l
ever its conformation is different from that of the green monomers a
in the seed and it forms a different acceptor surface to which fur-
Tther type b monomers may be added. The resulting “strain 2” fibril
fdiffers from the seed. Strain switch can also occur when the host
PrPC has the same sequence as the incoming PrPSc (not shown). d
(C) Strain incompatibility. The PrPC type c (blue) has a sequence e
different from that of the PrPSc and can either not attach to the b
seed’s acceptor surface or attach but not form an acceptor surface
for further monomer addition. In the latter case not only is the strain
snot propagated, but it can prevent monomers of a compatible type
sfrom adding to the seed, thus exerting a dominant-negative effect.
aFinal proof that the prion consists of only protein
ould be achieved if pure PrPC or, better yet, recombi-
ant PrP (rPrP) produced in E. coli, could be converted
nto a form that elicits prion disease. A first, seminal
tep in that direction was the demonstration that incu-
ation of radioactive PrPC with unlabeled PrPSc in a
ell-free system generated radioactive PrPSc, as char-
cterized by its physical properties (Caughey et al.,
999). Moreover, the in vitro reaction reflected the spe-
ies and strain-specific barriers recognized in vivo, but
n increase of infectivity was not demonstrated. An im-
ortant advance was provided by the invention of pro-
ein misfolding cyclic amplification (PMCA). In a recent
eport (Castilla et al., 2005), prion-infected hamster
rain homogenate, as a source of PrPSc, was diluted
0−4 with uninfected brain homogenate, a source of
rPC, incubated, and sonicated to fragment aggregates
nd thereby augment seeding; incubation and sonica-
ion were repeated 20 times. The reaction mixture was
hen diluted 1:10 into uninfected brain homogenate and
gain subjected to incubation and sonication. After re-
eated cycles of dilution and amplification, the original
nfected brain homogenate had been diluted 10−20-fold
nd the original PrPSc was calculated to have been
ompletely removed. Nonetheless, the level of PrPSc re-
ained essentially as in the initial 10−4 diluted brain ho-
ogenate. Importantly, infectivity was also found, as
hown by the bioassay in hamsters. However, the incu-
ation time was very significantly longer than that elic-
ted by the original brain, either because the specific
nfectivity attributed to the newly formed PrPSc was
ower than that of its “natural” counterpart or because
“strain shift” of the prion (see below) had occurred.
his experiment convincingly shows that PrPSc and in-
ectious agent had been generated in vitro; however it
oes not exclude amplification of other molecules, for
xample nucleic acids, because it was carried out with
rain homogenate and not with purified components.
rPrP prepared from E. coli can be converted into β
heet-rich fibrillar forms in a cell-free system without
eeding by PrPSc (Bocharova et al., 2005). Legname et
l. (Legname et al., 2004) injected a β sheet-rich fibrillar
reparation derived from amino-terminally truncated
PrP (extending from residue 89 to 230) intracerebrally
nto mice overexpressing PrP with the same deletion
tg9949 mice). All mice developed neurological disease
fter about 520 days, as compared with an incubation
ime of around 160 days caused by the “natural” RML
rion strain. Tg9949 mice injected with only PBS were
ealthy at 620 days; however, their later fate was not
eported. Brain homogenate from the sick tg9949 mice
licited disease after about 260 days when injected into
g9949 mice. Importantly, disease could also be trans-
itted to wild-type mice. The authors’ conclusion is
hat the fibrillar preparation of rPrP contained “syn-
hetic prions,” perhaps at low levels, and that these
ere amplified or underwent a strain shift (or both) in
he tg9949-inoculated mice, accounting for the short-
ned incubation period on further propagation. An al-
ernative explanation offered in commentaries to the
aper is that the tg9949-transgenic mice, which greatly
verproduce (truncated) PrP, would have spontane-
usly developed prion disease with advancing age and
hat the inoculation somehow accelerated this endoge-
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167nous process. Indeed, the critical control experiment
of injecting brain homogenate from old, noninoculated
tg9949 into young tg9949 mice and monitoring for the
appearance of prion disease was not reported. How-
ever, one should not lose sight of the undisputable sig-
nificance of this experiment, namely that if prions had
not been generated in the cell-free system, they must
have arisen spontaneously in an uninfected mouse,
mimicking the sporadic occurrence of Creutzfeldt-
Jakob disease in man. To paraphrase Samuel Johnson:
The report on de novo generation of prions is like “a
dog’s walking on his hind legs. It is not done well; but
you are surprised to find it done at all.”
The interpretation of the Legname experiment is,
however, critical in one regard. If the prions in the
tg9949 mice are of endogenous origin then the experi-
ment would not constitute proof of the protein-only hy-
pothesis; my mind’s ear hears the perennial murmur-
ings in the wings, invoking endogenous, perhaps
retroviral viruses. If however prions had been generated
in vitro from recombinant PrP, then the proof would be
indisputable, even if amplification required additional
components provided by the host, such as RNA (De-
leault et al., 2003).
Multiplication of Yeast Prions
Inasmuch as one is willing to accept a conformational
variant of a yeast protein as a prion, prion multiplication
can be studied much more readily in yeast than in
mammals (reviewed in Wickner et al., 2004). For exam-
ple, the S. cerevisiae protein sup35p, a component of
the translation termination factor, spontaneously con-
verts at low frequency to an aggregated, functionally
impaired form, which then recruits other sup35p mole-
cules into the prion state. This state is passed onto the
progeny of the [PSI+] cell. Several factors promoting or
counteracting conversion were identified, and the pro-
tein segment (“prion domain,” Sup-NM) of sup35p nec-
essary and sufficient for conversion was delineated.
Prolonged incubation in vitro of purified sup35p or Sup-
NM results in spontaneous formation of amyloid fibers,
and this process is greatly accelerated by extracts from
[PSI+] yeast or fibers preformed in vitro, providing po-
tent support for the seeding hypothesis.
Prion Strain and Species Barriers
Because distinct mammalian prion strains can be prop-
agated indefinitely in hosts homozygous for the PrP
gene, the protein-only hypothesis demands that the
strain-specific properties be enciphered in some fea-
ture of the pathogenic PrP other than its amino acid
sequence, such as posttranslational modification or
conformation. In fact, different strains are often associ-
ated with PrPSc species differing in physical properties
such as susceptibility to PK digestion, electrophoretic
mobility following PK treatment reflecting different
cleavage sites in the amino-proximal region, stability
toward denaturation agents, or the ratio of di-, mono-,
and unglycosylated forms. The conformation-depen-
dent immunoassay (CDI) provides a sensitive tool for
differentiating between different conformations of PrP
associated with distinct prion strains.
“Conformation templating” at the protein level was
first demonstrated by showing that when radioactive
PrPC was incubated with PrPSc derived from strains dif-
fering in the electrophoretic mobility of their PK-resis-tant moiety, the radioactive conversion product showed
the strain-specific properties of the PrPSc template
(Caughey et al., 1999). Experiments with yeast [PSI+]
prions conclusively demonstrated that different strain
properties are associated with different fibrillar confor-
mations of the underlying sup35 protein. King et al. iso-
lated fibrous aggregates consisting of a Sup35 prion
domain from three distinct [PSI+] yeast strains. Bacteri-
ally expressed, tagged sup35 prion domain prepara-
tions were seeded with these aggregates and the re-
sulting fibers were introduced into yeast, where they
elicited the [PSI+] state characteristic for the donor
lines (King and Diaz-Avalos, 2004). A different approach
led to the same conclusion: amyloids formed de novo
from the Sup35 prion domain (Sup-NM) at different
temperatures adopted distinct, stably propagating con-
formations, as characterized by thermal stability and
electron paramagnetic resonance spectroscopy, and
infection of yeast with these amyloids led to distinct
[PSI+] strains (Tanaka et al., 2004).
As regards mammalian prion strains, although rPrP,
both truncated and full-length, can be converted into
fibrillar amyloid forms that can be propagated by seed-
ing (Bocharova et al., 2005; Jones and Surewicz, 2005),
the infectivity of such preparations is at best low (Leg-
name et al., 2004). Although correlation of structurally
different fibrils with distinct prion strains has not been
achieved so far, interesting insights regarding their
seeding properties have been obtained (Jones and
Surewicz, 2005), as described below.
Transmission Barriers
Incubation time, the time elapsing between inoculation
and appearance of clinical symptoms, is not a simple
function of prion or PrPSc accumulation but is depen-
dent on the prion strain, the site of inoculation within
the brain, and genetic determinants of the host other
than the PrP gene. As judged by incubation time, trans-
mission of prions from one species to another is usually
less efficient than intra-species transmission, a phe-
nomenon attributed to a “species barrier.” Further
transmission into individuals of the recipient species
typically results in shortening of the incubation time.
Prions thus appear to “adapt” to the trans-species
host. The transmission barrier between species is at-
tributed to a mismatch between the amino acid se-
quence of the donor PrPSc and the PrPC of the recipi-
ent, and in many instances replacement of the PrP
gene of the mouse by that of the prion donor abolishes
the barrier. “Adaptation” is attributed to the formation
of PrPSc consisting of the host PrP. Interestingly, a sin-
gle amino acid change in the PrP of a recipient mouse
can cause a profound change in the incubation time
(Manson et al., 1999) or even virtually abrogate suscep-
tibility (dominant-negative mutations, see Figure 1)
(Perrier et al., 2002). Similarly, natural polymorphisms of
the PrP gene, for example in position 129 of the human
protein, have a profound effect on susceptibility to spo-
radic CJD (sCJD) and even more so to variant CJD
(vCJD).
Different mouse prion strains, raised in mice with the
same PrP gene, show different incubation times in a
particular mouse line, as do human-derived vCJD and
sCJD prions transmitted to mice. This demonstrates
that features other than the PrP sequence or the host
Cell
168Sgenotype, presumably the conformation of the PrP*, co-
determine incubation times. Longer incubation times and
Alow attack rates are attributed to a “strain barrier.”
BLikely both the strain and the species barrier have a
B
similar origin, namely the inability of PrPC to adopt a
B
conformation suitable for efficient seed propagation,
C
the only difference being that for the strain barrier con-
C
formational space is inherent to one particular PrP se- B
quence while for the species barrier conformational t
space is co-determined by sequence variation. C
Insight into the mechanism of transmission barriers is D
brought by recent studies in vitro on PrP-derived fibrils. 4
Surewicz and his colleagues (Jones and Surewicz, G
B2005) found that fibrils generated from human and
Hmouse carboxy-terminally truncated recombinant PrP
(PrP23–144) had similar morphologies and spectro- J
scopic properties that differed from those of their Syr- K
1ian hamster counterparts. Interestingly, human and
Kmouse fibrils could seed homologous as well as each
Lother’s monomers, however not hamster monomers.
DHamster fibrils could seed mouse but not human mono-
Mmers, reflecting an asymmetric seeding barrier. Such
Masymmetric barriers may be due to the conformational
(
space available to the different PrP sequences (Col-
P
linge, 1999; Tanaka et al., 2005): thus, mouse mono- m
mers can assume a conformation that allows them to P
add to a Syrian hamster seed, but the hamster mono- T
mers cannot assume the conformation that would allow (
their addition to a mouse seed. Interestingly, fibrils T
1formed by addition of mouse monomers to a hamster
Useed show the physical and seeding properties of ham-
1ster, rather than mouse fibrils. This explains the in vivo
Wphenomenon designated “primacy of strain”: often,
Wstrain-specific properties of a prion are preserved even
Bafter transmission from one species to another and
6back, although the PrP sequences of the two species
are very different (Kimberlin et al., 1987; Tanaka et al.,
2005). Interesting as they are, the observations made
using an amino-proximal fragment of unglycosylated
PrP cannot be expected to fully reflect the properties
of prions, in particular infectivity.
A model for strain perpetuation, strain switch, and
strain incompatibility within the framework of the seed-
ing hypothesis is summarized in Figure 1.
Conclusions
It has been convincingly established that prions can be
propagated in a cell-free, albeit complex environment.
Moreover, it has been shown that prions can arise de
novo in an experimental system, although it is unclear
whether this spontaneous generation took place in a
cell-free system or in the mouse. Finally, incontrovert-
ible evidence has accumulated that strain specificity
can be encoded at the level of protein conformation.
Many questions still remain to be answered. Does the
mammalian prion consist of only a conformer of PrP or
are other components required to generate it or render
it infectious? Is the PrP conformer PrPSc, a fibrillar form
of PrP, or some as yet not characterized isoform? How
do prions exercise their pathogenic potential and how
are different prion strains targeted to different brain re-
gions? Postdocs rejoice! There is yet much work to be
done.elected Reading
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